BIOCAD and SPH agree to build a drug substance manufacturing facility in China - (The Economic Times via NewsPoints Desk)

  • Biocad and Shanghai Pharmaceuticals inked a memorandum of understanding to create two joint ventures focused on the development of monoclonal antibodies for the Chinese market, as reported The Economic Times.

  • The joint ventures will seek to develop and commercialise at least six of Biocad's pipeline assets for malignancies and autoimmune diseases.

  • "We believe that transferring Biocad's technologies to a jointly-owned manufacturing facility in China will boost our pharmaceutical exports," commented CEO Dmitry Morozov.

  • Construction of an active pharmaceutical ingredient manufacturing facility for the joint ventures could start as soon as next year.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.